Xiangyu Medical(688626)

Search documents
翔宇医疗(688626) - 2021 Q1 - 季度财报
2021-04-27 16:00
Financial Performance - Net profit attributable to shareholders increased by 64.20% to CNY 34,147,165.81 year-on-year[17] - Operating revenue rose by 53.83% to CNY 100,769,121.63 compared to the same period last year[17] - The total profit for Q1 2021 was ¥38,919,592.29, up 64.9% from ¥23,598,200.40 in Q1 2020[48] - Net profit for Q1 2021 was ¥33,973,422.33, representing a 63.5% increase from ¥20,763,360.48 in Q1 2020[48] - The total comprehensive income for the first quarter of 2021 was CNY 22,072,885.83, compared to CNY 16,509,825.19 in the same period of 2020, representing a year-over-year increase of approximately 33.5%[53] Asset Growth - Total assets increased by 106.42% to CNY 2,026,034,977.22 compared to the end of the previous year[17] - The total assets reached ¥2,026,034,977.22, a significant increase from ¥981,533,777.07, indicating strong growth in the company's financial position[31] - Total assets reached ¥2,026,761,785.09, compared to ¥929,242,930.76, indicating an increase of around 118.0%[42] - The total current assets amounted to ¥1,659,854,046.67, up from ¥567,047,074.84, reflecting an increase of about 192.0%[40] Cash Flow - Net cash flow from operating activities improved by 121.28% to CNY 5,170,963.76 compared to the previous year[17] - The net cash flow from operating activities was CNY 5,170,963.76, a recovery from a negative cash flow of CNY 24,304,022.66 in the first quarter of 2020[56] - Cash inflows from operating activities amounted to CNY 126,169,228.08, significantly up from CNY 46,783,460.92 in the first quarter of 2020, indicating a growth of about 169.5%[56] - The company raised ¥1,022,435,905.55 through its initial public offering, marking a 1,945.80% increase in cash flow from financing activities compared to ¥49,977,222.22 in the previous period[25] - Cash and cash equivalents increased by 209.26% to CNY 1,506,843,837.25 due to the proceeds from the IPO[23] Liabilities and Equity - Total liabilities increased to ¥199,118,254.21 from ¥238,247,030.59, reflecting a decrease of approximately 16.4% year-over-year[36] - Owner's equity rose significantly to ¥1,826,916,723.01 from ¥743,286,746.48, marking an increase of about 145.0%[36] - The company's capital reserve increased significantly by 353.79% to ¥1,295,042,226.23 from ¥285,385,672.03, attributed to the premium from the initial public offering[25] - The company's capital reserve increased to ¥1,296,839,308.02 from ¥287,182,753.82, a rise of approximately 351.0%[42] Research and Development - R&D investment as a percentage of operating revenue increased by 4.55 percentage points to 12.73%[17] - R&D expenses surged by 139.29% to ¥12,827,992.23 from ¥5,360,925.25, driven by increased investment in ongoing projects and higher personnel costs[25] - Research and development expenses in Q1 2021 amounted to ¥12,827,992.23, which is a 138.5% increase from ¥5,360,925.25 in Q1 2020[46] Shareholder Information - The number of shareholders at the end of the reporting period was 22,436[20] - Basic earnings per share for Q1 2021 were ¥0.21, compared to ¥0.17 in Q1 2020, reflecting a 23.5% increase[48] Other Income and Expenses - The company reported a significant increase in other income, which rose by 179.74% to ¥7,378,194.95 from ¥2,637,526.54, primarily due to increased government subsidies[25] - Sales expenses increased by 62.52% to ¥19,515,122.46 from ¥12,007,687.36, largely due to lower travel and marketing expenses in the previous period[25] - Management expenses in Q1 2021 reached ¥6,743,663.11, up 27.9% from ¥5,270,746.50 in Q1 2020[46]